Systemic Sclerosis

Evidence-Based Rheumatology

Volumn , Issue , 2009, Pages 443-493

  Furst, Daniel E ^a   Pope, Janet ^b   Clements, Phil ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Alpha blockers prazosin, phenoxybenzamine; Alpha interferon in systemic sclerosis; Antioxidant therapy; Disease modifying antirheumatic drugs (DMARDs); Epoprostenol versus placebo; Potassium aminobenzoate (POTABA); Raynaud's phenomenon in systemic sclerosis; Scleroderma and methotrexate; Systemic sclerosis; Systemic sclerosis (SSc) multifaceted, autoimmune disease

Indexed keywords

EID: 84889414617     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444315844.ch12     Document Type: Chapter

References (88)

1. Clements PJ, Furst DE. Pathogenesis, Fusion (Summary). Systemic Sclerosis. Baltimore: Williams and Wilkins, 1996: 274-85.
2. Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Arthritis Rheum 1989; 32: 584-93.
3. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-44.
4. White B, Moore W, Wigley F, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.
5. Casas JA, Saway PA, Villarreal I, et al. 5-Fluorouracil in the treatment of scleroderma: A randomised, double-blind, placebo-controlled international collaborative study. Ann Rheum Dis 1990; 49: 926-8.
6. Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomised double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35(4): 364-72.
7. Pope J, Bellamy N, Seibold J, et al. A randomised controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-8.
8. Binks M; Passweg JR; Furst D; McSweeney P, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60(6): 577-84.
9. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100(5): 1602-10.
10. McKown KM, Carbone LD, Bustillo J, et al. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 2000; 43(5): 1054-61.
11. A.Sharada, A Kumar, R Kakkar, et al. Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis: a randomised placebo-controlled trial. Rheumatol Int 1994; 14: 91-4.
12. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomised, controlled trial. Ann Intern Med 2000; 132(6): 425-34.
13. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999; 116: 914-20.
14. Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001; 22(3): 529-37.
15. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomised, placebocontrolled trial. Am J Respir Crit Care Med 2002; 165(6): 800-4.
16. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120(5): 1562-9.
17. Iwabuchi H, Kasama T, Hanaoka R: Downregulation of intercellular adhesion molecule-1 expression on human synovial fibroblasts by endothelin-1. J Rheumatol 1999; 26(3): 522-31.
18. Rubin LF, Badesch DB, Barst RJ. Bosentan therapy for pulmonary arterial hypertension. NEJM 2002; 346: 896-903.
19. Zawada ET Jr, Clements PJ, Furst DE, et al. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron 1981; 27: 74-8.
20. Thurm RH, Alexander JC. Captopril in the treatment of scleroderma renal crisis. Arch Intern Med 1984; 144: 733-55.
21. Beckett VL, Donadio JV, Brennan LA Jr, et al. Use of captopril as early therapy for renal scleroderma: A prospective study. Mayo Clin Proc 1985; 60: 763.
22. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 17: 600-3.
23. Beckett VL, Conn DL, Ruster V, et al. Trial of plateletinhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 1984; 27: 1137-43.
24. Furst DE, Clements PJ, Harris R, et al. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of Nacetylcysteine. Ann Rheum Dis 1979; 38: 356-61.
25. Grassegger A, Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomised controlled multicentre trial. Br J Dermatol 1998; 139: 639-48.
26. Ziesche R, Hofbauer E, Wittman K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. NEJM 1999; 341: 264-9.
27. Black{incomplete} Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42: 299-305.
28. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two year, double-blind, randomised, controlled clinical trial. Arthritis Rheum 1999; 42(6): 1194-203.
29. Seibold JR, Korn JH, Simms R, et al. Recombinant Human Relaxin in the Treatment of Scleroderma; a randomised, double-blind, placebo controlled trial. Ann Intern Med 2000; 32: 871-9.
30. Williams HJ, Furst DE, Dahl SL, et al. Double-blind, multi-center controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis Rheum 1985,28: 308-14.
31. Gibson T, Graham R. Cyclofenil treatment of scleroderma-a controlled study. Br J Rheumatol 1983; 22: 218-23.
32. Blom-Bulow B, Berg K, Wilhelm RA, et al. Cyclofenil versus placebo in progressive systemic sclerosis. A oneyear double-blind crossover study of 27 patients. Acta Med Scand 1981; 210: 419-28.
33. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin 2001; 13(6): 505-11.
34. Siriwardena D, Khaw PT, King AJ, et al. Human antitransforming growth factor beta(2) monoclonal antibody-a new modulator of wound healing in trabeculectomy: a randomised placebo controlled clinical study. Ophthalmology 2002; 109: 427-31.
35. Furst D. Personal communication, 2003.
36. Zarafonetis CJD, Dubach L, Skovronski JJ, et al. Retrospective studies in scleroderma: skin response to para-aminobenzoate therapy. Clin Exp Rheumatol 1988; 6: 261-8.
37. Clegg DO, Reading JC, Mayes MD, et al. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol 1994; 21: 105-10. 1994.
38. Cannella AC, Reading JC, Clegg DO. Aminobenzoate potassium improves mortality in patients with scleroderma. Arth Rheum 2003; 46(Suppl): s358.
39. Gruber BL, Kaufman LD: A double-blind randomised controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum 1991; 34: 362-5.
40. Herrick AL, Hollis S, Schofield D, et al. A double-blind, placebo-controlled trial of antioxidant therapy in limited cutaneous sclerosis. Clin Exper Rheum 2000; 18: 349-56.
41. Kelley W, Harris E, Ruddy S, Sludge C. Textbook of Rheumatology, 5th edn. Philadelphia: W.B. Saunders Company, 1997.
42. Freedman R, Ianni P, Wenig P. Behavioral treatment of Raynaud's phenomenon in scleroderma. J Behav Med 1984; 7(4): 343-53.
43. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44(8): 1841-7.
44. Weber A, Bounameaux H. Effects of low-dose nifedipine on a cold provocation test in people with Raynaud's disease. J Cardiovasc Pharmacol 1990; 15: 853-5.
45. Sarkozi J, Bookman A, Mahon W, et al. Nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol 1986; 13: 331-6.
46. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: Cochrane Collaboration. Cochrane Library. Issue 1, 2002. Oxford: Update Software.
47. Black CM, Halkier-Sorensen L, Belch JJF, et al. Oral Iloprost in Raynaud's phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998; 37(9): 952-60.
48. Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's sydrome. Ann Rheum Dis 1985; 44(11): 754-60.
49. Pope J, Fenlon D, Thompson A, et al. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: Cochrane Collaboration. Cochrane Library. Issue 1, 2002. Oxford: Update Software.
50. Coffman J, Clement D, Creager M, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989; 87: 264-8.
51. Davinroy M, Mosnier M. Evaluation clinique en doubleinsu du naftidrofuryl dans le phenomene de raynaud. Actualite Therapeutique 1993; 69: 1322-26.
52. Haavik Nilson K. Effects of naftidrofuryl on microcirculatory cold sensitivity in Raynaud's phenomenon. Br Med J 1979; 1(6155): 20-21.
53. Surwit RS, Gilgor RS, Allen LM, Duvic M. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. Arch Dermatol 1984; 120(3): 329-31.
54. Wollersheim H, Thien T, Fennis J, Van Elteren P, Van't Laar A. Double-blind, placebo-controlled study of Prazosin in Raynaud's phenomenon. Clin Pharmacol Ther 1986; 40(2): 219-25.
55. Russell IJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double-blind, single-crossover study. J Rheumatol 1985; 12(1): 94-8.
56. Cleophas T, Van Lier H, Fennis J, Van't Laar A. Treatment of Raynaud's syndrome with adrenergic alpha-blockade with or without beta-blockade. Angiology 1984; 35(1): 29-37.
57. Holti G. A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud's phenomenon. Curr Med Res Opin 1979; 6(4): 267-70.
58. Black C, Korn J, Mayes M, et al. Prevention of ischemic digital ulcers in systemic sclerosis by endothelin receptor antagonism. Arthritis Rheum 2002; 46: 3414.
59. Blom-Bulow B, Oberg K, Wollheim FA, et al. Cyclofenil versus placebo in progressive systemic sclerosis. A one year double-blind crossover study of 27 patients. Acta Med Scand 1981; 210(5): 419-28.
60. Nahir AM, Schapira D, Scharf Y. Double-blind, randomised trial of Nitroderm TTS in the treatment of Raynaud's phenomenon. Isr J Med Sci 1986; 22(2): 139-42.
61. Teh LS, Manning J, Moore T, Tully MP, O'Reilly D, Jayson M. Sustained-release transdermal glyceryl trinitrate
62. Kelley W, Harris E, Ruddy S, Sludge C. Textbook of Rheumatology, 5th edn. Philadelphia: W.B. Saunders Company, 1997.
63. Freedman R, Ianni P, Wenig P. Behavioral treatment of Raynaud's phenomenon in scleroderma. J Behav Med 1984; 7(4): 343-53.
64. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44(8): 1841-7.
65. Weber A, Bounameaux H. Effects of low-dose nifedipine on a cold provocation test in people with Raynaud's disease. J Cardiovasc Pharmacol 1990; 15: 853-5.
66. Sarkozi J, Bookman A, Mahon W, et al. Nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol 1986; 13: 331-6.
67. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: Cochrane Collaboration. Cochrane Library. Issue 1, 2002. Oxford: Update Software.
68. Black CM, Halkier-Sorensen L, Belch JJF, et al. Oral Iloprost in Raynaud's phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998; 37(9): 952-60.
69. Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's sydrome. Ann Rheum Dis 1985; 44(11): 754-60.
70. Pope J, Fenlon D, Thompson A, et al. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: Cochrane Collaboration. Cochrane Library. Issue 1, 2002. Oxford: Update Software.
71. Coffman J, Clement D, Creager M, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989; 87: 264-8.
72. Davinroy M, Mosnier M. Evaluation clinique en doubleinsu du naftidrofuryl dans le phenomene de raynaud. Actualite Therapeutique 1993; 69: 1322-26.
73. Haavik Nilson K. Effects of naftidrofuryl on microcirculatory cold sensitivity in Raynaud's phenomenon. Br Med J 1979; 1(6155): 20-21.
74. Surwit RS, Gilgor RS, Allen LM, Duvic M. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. Arch Dermatol 1984; 120(3): 329-31.
75. Wollersheim H, Thien T, Fennis J, Van Elteren P, Van't Laar A. Double-blind, placebo-controlled study of Prazosin in Raynaud's phenomenon. Clin Pharmacol Ther 1986; 40(2): 219-25.
76. Russell IJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double-blind, single-crossover study. J Rheumatol 1985; 12(1): 94-8.
77. Cleophas T, Van Lier H, Fennis J, Van't Laar A. Treatment of Raynaud's syndrome with adrenergic alpha-blockade with or without beta-blockade. Angiology 1984; 35(1): 29-37.
78. Holti G. A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud's phenomenon. Curr Med Res Opin 1979; 6(4): 267-70.
79. Black C, Korn J, Mayes M, et al. Prevention of ischemic digital ulcers in systemic sclerosis by endothelin receptor antagonism. Arthritis Rheum 2002; 46: 3414.
80. Blom-Bulow B, Oberg K, Wollheim FA, et al. Cyclofenil versus placebo in progressive systemic sclerosis. A one year double-blind crossover study of 27 patients. Acta Med Scand 1981; 210(5): 419-28.
81. Nahir AM, Schapira D, Scharf Y. Double-blind, randomised trial of Nitroderm TTS in the treatment of Raynaud's phenomenon. Isr J Med Sci 1986; 22(2): 139-42.
82. Teh LS, Manning J, Moore T, Tully MP, O'Reilly D, Jayson M. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheum 1995; 34(7): 636-41.
83. Ettinger W, Wise RA, Schaffhauser D, Wigley FM. Controlled double-blind trial of Dazoxiben and Nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1984; 77(3): 451-6.
84. Luderer JR, Nicholas GG, Neumyer MM, et al. Dazoxiben, a thromboxane synthetase inhibitor in Raynaud's phenomenon. Clin Pharmacol Ther 1984; 36(1): 105-15.
85. Coffman JD, Rasmussen HM. Effect of thromboxane synthetase inhibition in Raynaud's phenomenon. Clin Pharmacol Ther 1984; 36(3): 369-73.
86. Belch JJ, Cormie J, Newman P, et al. Dazoxiben, a thromboxane synthetase inhibitor in the treatment of Raynaud's syndrome: a double-blind trial. J Clin Pharmac 1983; 15(suppl 1): 113S-116S.
87. Destors J, Gauthier E, Lelong S, Boissel J. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon. Angiology 1986; 37: 565-9.
88. Maurel A, Betrancourt J-C, Van Frenkel R, Thuillez C. Action du buflomedil sur la microcirculation cutanée etudiée par un test de provacation au froid. Etude multicentrique, double aveugle versus placebo. J Maladies Vasculaires 1995; 20: 127-33.